Telomir Pharmaceuticals, Inc.

Zacks says take a look at the stock ahead of human trials of Telomir's primary drug early next year



Zacks reiterates recommendation on anti-aging drugmaker Telomir despite 47% YTD loss

Vigil Neuroscience, Inc.

Sanofi

Eli Lilly and Company

Shares of Vigil Neuroscience, a small drugmaker specializing in rare and common neurodegenerative diseases, <a href="https://finance.yahoo.com/quote/VIGL/">skyrocketed</a> over 240% yesterday, May 22, on <a href="https://investors.vigilneuro.com/news-releases/news-release-details/vigil-neuroscience-enters-definitive-merger-agreement-be">news</a> that pharmagiant Sanofi would acquire the company. This marks Sanofi’s entry into the race to develop an Alzheimer’s treatment, which, <a href="https://oninvest.com/article/pat-small-cap-kompanij-sposobnyh-zarabotat-na-terapii-bolezni-al-cgejmera">according</a> to Bloomberg, might turn into the next obesity market.

Biotech small cap Vigil soars 240% on news of acquisition by pharma giant Sanofi 


Longeveron Inc.

Zacks Small-Cap Research (Zacks SCR) <a href="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_03202025_LGVN_Sorensen.pdf">believes</a> that Longeveron, a micro-cap developer of cellular therapies for aging-related diseases, is worth more than five times its current share price. Its outlook has been bolstered after U.S. authorities gave the <a href="https://scr.zacks.com/news/news-details/2025/LGVN-Announces-Positive-Alzheimers-News/default.aspx">green light</a> to trials of the company’s Alzheimer’s drug and granted it a special designation. Overall, Alzheimer’s drugs are <a href="https://www.bloomberg.com/news/articles/2025-01-10/alzheimer-s-drugs-from-lilly-novo-and-roche-in-focus-for-investors?sref=Y0jVLcFo&amp;utm_source=in_materials#:~:text=Investors%20seeking%20the%20next%20obesity%2Dlike%20market%20opportunity%20will%20be%20closely%20watching%20developments%20related%20to%20treatments%20for%20Alzheimer%E2%80%99s%20disease%20in%202025.">seen</a> as a highly promising niche for investors.

#Alzheimer's disease: 3

Zacks reiterates recommendation on anti-aging drugmaker Telomir despite 47% YTD loss

Biotech small cap Vigil soars 240% on news of acquisition by pharma giant Sanofi

Zacks sees Alzheimer's drugmaker Longeveron as massively undervalued